title: Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
abstract: OBJECTIVE
  To clarify the prognostic role of E-cadherin and beta- and gamma-catenins, and their relation to CD44 in epithelial ovarian carcinoma.
  
  
  METHODS
  The expression of E-cadherin and beta- and gamma-catenins was analysed immunohistochemically in 305 primary epithelial ovarian cancers and 44 metastases, and related to CD44 expression, clinicopathological factors, and the patients' survival.
  
  
  RESULTS
  Reduced cell surface expression of E-cadherin, beta-catenin, and gamma-catenin was particularly frequent in serous and endometrioid histological types. Reduced cell surface expression of E-cadherin and beta-catenin was also associated with poor differentiation. Nuclear positivity of beta-catenin was associated with high CD44 expression, endometrioid histology, and local stage of the tumour, whereas nuclear gamma-catenin expression was associated with serous histology and poor differentiation. In the univariate analysis, preserved cell surface beta-catenin expression in the whole study material and nuclear expression of beta- and gamma-catenins in the subgroup of endometrioid ovarian cancers were predictors of better 10 year disease related survival. Preserved cell surface expression of E-cadherin and beta-catenin predicted favourable recurrence-free survival. These statistical significances were not retained in multivariate analysis.
  
  
  CONCLUSIONS
  The correlation between nuclear beta-catenin and CD44 indicates that beta-catenin may regulate the transcription of CD44 in epithelial ovarian cancer. E-cadherin-catenin complex members are associated with the prognosis of patients with epithelial ovarian cancer, but these univariate associations were not strong enough to compete for significance with the traditional clinicopathological factors.
authors.affiliation: Department of Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Finland.
authors.forename: K A
authors.initials: KA
authors.lastname: Voutilainen
authors.forename: M A
authors.initials: MA
authors.lastname: Anttila
authors.forename: S M
authors.initials: SM
authors.lastname: Sillanpää
authors.forename: K M
authors.initials: KM
authors.lastname: Ropponen
authors.forename: S V
authors.initials: SV
authors.lastname: Saarikoski
authors.forename: M T
authors.initials: MT
authors.lastname: Juhola
authors.forename: V-M
authors.initials: VM
authors.lastname: Kosma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D007150:Immunohistochemistry / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate; D051176:beta Catenin / Q000032:analysis*; D051185:gamma Catenin / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D018960:Hyaluronan Receptors; D051176:beta Catenin; D051185:gamma Catenin